var data={"title":"Erwinia asparaginase: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Erwinia asparaginase: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/489390?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=erwinia-asparaginase-patient-drug-information\" class=\"drug drug_patient\">see &quot;Erwinia asparaginase: Patient drug information&quot;</a> and <a href=\"topic.htm?path=erwinia-asparaginase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Erwinia asparaginase: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48847933\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Erwinaze/Erwinase Safety Alert</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">Particulate matter has been observed bound to the stopper and/or present on the lyophilized cake in some vials of <i>Erwinaze</i> [US product] and <i>Erwinase </i>[Canadian product].</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Vials with visible particulate matter should not be administered. If there is no visible particulate matter after reconstitution, health care professionals should use a standard 5-micron filter needle to withdraw the reconstituted product from the vial prior to administration as an additional precaution. Erwinaze vials from certain batches should <b>only</b> be administered intramuscularly.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information, including affected batch and lot numbers, can be found at:</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Erwinaze [US]: http://erwinazesupply.com/product-updates/</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Erwinase [Canada]: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63916a-eng.php</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13388919\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Erwinaze</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13382001\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Erwinase</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13381923\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Enzyme;</li>\n      <li>\n        Antineoplastic Agent, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389045\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If administering IV, consider monitoring nadir serum asparaginase activity (NSAA) levels; if desired levels are not achieved, change to IM administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia (ALL):</b> IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>As a substitute for pegaspargase:</i> 25,000 units/m<sup>2</sup> 3 times weekly (Mon, Wed, Fri) for 6 doses for each planned pegaspargase dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>As a substitute for asparaginase (E. coli):</i> 25,000 units/m<sup>2</sup> for each scheduled asparaginase (<i>E. coli</i>) dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389044\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=erwinia-asparaginase-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Erwinia asparaginase: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If administering IV, consider monitoring nadir serum asparaginase activity (NSAA) levels; if desired levels are not achieved, change to IM administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia (ALL):</b> Children &ge;1 year and Adolescents: IM, IV: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ALL induction: </b> <i>Canadian labeling (not in the US labeling): </i>Children &lt;14 years: IM: 6,000 units/m<sup>2</sup> 3 times weekly for 9 doses beginning day 4 of week 1 (in combination with vincristine, prednisone, methotrexate, and daunorubicin)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389049\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389048\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended for other asparaginase products for hepatotoxicity during treatment (Stock 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALT/AST &gt;3 to 5 times ULN: Continue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALT/AST &gt;5 to 20 times ULN: Delay next dose until transaminases &lt;3 times ULN</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ALT/AST &gt;20 times ULN: Discontinue therapy if takes longer than 1 week for transaminases to return to &lt;3 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct bilirubin &lt;3 mg/dL: Continue therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct bilirubin 3.1 to 5 mg/dL: Hold asparaginase and resume when direct bilirubin &lt;2 mg/dL; consider switching to alternate asparaginase product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Direct bilirubin &gt;5 mg/dL: Discontinue asparaginase; do not substitute other asparaginase products; do not make up for missed doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389047\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemorrhagic or thrombotic event:</b> Discontinue treatment; may resume treatment upon symptom resolution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild pancreatitis: Withhold treatment until signs and symptoms subside and amylase levels return to normal; may resume after resolution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe or hemorrhagic pancreatitis (abdominal pain &gt;72 hours and amylase &ge;2 x ULN): Discontinue treatment; further use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Serious hypersensitivity reaction:</b> Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>The following adjustments have also been recommended for asparaginase products (Stock 2011):</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperammonemia-related fatigue:</b> Continue therapy for grade 2 toxicity. If grade 3 toxicity occurs, reduce dose by 25%; resume full dose when toxicity &le; grade 2 (make up for missed doses). If grade 4 toxicity occurs, reduce dose by 50%; resume full dose when toxicity &le; grade 2 (make up for missed doses).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hyperglycemia:</b> Continue therapy for uncomplicated hyperglycemia. If hyperglycemia requires insulin therapy, hold asparaginase (and any concomitant corticosteroids) until blood glucose controlled; resume dosing at prior dose level. For life-threatening hyperglycemia or toxicity requiring urgent intervention, hold asparaginase (and corticosteroids) until blood glucose is controlled with insulin; resume asparaginase and do not make up for missed doses. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity reactions:</b> May continue dosing for urticaria without bronchospasm, hypotension, edema, or need for parenteral intervention. If wheezing or other symptomatic bronchospasm with or without urticaria, angioedema, hypotension, and/or life-threatening hypersensitivity reactions occur, discontinue asparaginase.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertriglyceridemia:</b> If serum triglyceride level &lt;1000 mg/dL, continue asparaginase but monitor closely for pancreatitis. If triglyceride level &gt;1,000 mg/dL, hold asparaginase and monitor; resume therapy at prior dose level after triglyceride level returns to baseline. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pancreatitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asymptomatic amylase or lipase &gt;3 times ULN (chemical pancreatitis) or radiologic abnormalities only: Continue asparaginase and monitor levels closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symptomatic amylase or lipase &gt;3 times ULN: Hold asparaginase until enzyme levels stabilize or are declining.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Symptomatic pancreatitis or clinical pancreatitis (abdominal pain with amylase or lipase &gt;3 times ULN for &gt;3 days and/or development of pancreatic pseudocyst): Permanently discontinue asparaginase.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thrombosis and bleeding, CNS:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further asparaginase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemorrhage: Discontinue therapy; do not withhold therapy for abnormal laboratory findings without a clinical correlate. If grade 3 toxicity occurs, discontinue therapy; if CNS signs/symptoms are fully resolved and further asparaginase doses are required, may resume therapy at a lower dose and/or longer intervals between doses. Discontinue therapy for grade 4 toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Thrombosis and bleeding, non-CNS:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Thrombosis: Continue therapy for abnormal laboratory findings without a clinical correlate. If grade 3 or 4 toxicity occurs, withhold therapy until acute toxicity and clinical signs resolve and anticoagulant therapy is stable or completed. Do not withhold therapy for abnormal laboratory findings without clinical correlate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemorrhage: If grade 2 bleeding in conjunction with hypofibrinogenemia occurs, withhold therapy until bleeding &le; grade 1. Do not withhold therapy for abnormal laboratory findings without clinical correlate. For grade 3 or 4 bleeding, withhold therapy until bleeding &le; grade 1 and until acute toxicity and clinical signs resolve and coagulant replacement therapy is stable or completed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13388920\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erwinaze: 10,000 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389021\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389020\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">For order information contact 877-625-2566 or visit http://erwinaze.com/healthcare-professionals/order-erwinaze/</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389050\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      Note: Vials from certain batches should only be administered intramuscularly or require the use of a 0.2 micron filter if administered intravenously. Refer to the following for batch-specific information: http://erwinazesupply.com/product-updates/.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: The volume of each single injection site should be limited to 2 mL; use multiple injections for volumes &gt;2 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infuse over 1 to 2 hours; do not infuse other medications through the same IV line.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13381925\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute lymphoblastic leukemia:</b> Treatment (in combination with other chemotherapy) of acute lymphoblastic leukemia (ALL) in patients with hypersensitivity to <i>E. coli</i>-derived asparaginase</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13381921\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asparaginase <i>(Erwinia)</i> may be confused with asparaginase <i>(E. coli)</i>, pegaspargase</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Erwinaze may be confused with Elaprase, Elspar, Oncaspar</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389029\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency of adverse reactions is for both IM and IV routes unless specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Hypersensitivity: Hypersensitivity reaction (14% [IV: &le;37%]; grades 3/4: 4%; includes anaphylaxis, urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Thrombosis (2% [IV: &le;7%]; grades 3/4: &le;1%; includes pulmonary embolism and cerebrovascular accident)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperglycemia (4% [IV: &le;17%]; grades 3/4: 4%), abnormal transaminase (4%), decreased glucose tolerance (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3% [IV: &le;20%]), vomiting (3% [IV: &le;17%]), pancreatitis (4%; grades 3/4: &lt;1%), abdominal pain (1%), diarrhea (1%), mucositis (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anorexia, azotemia, bone marrow depression (rare), changes in serum lipids, chills, decreased serum albumin, decreased serum cholesterol, disseminated intravascular coagulation, headache, hemorrhage, hepatomegaly, hyperammonemia, hyperbilirubinemia, irritability, malabsorption syndrome, proteinuria, seizure, transient ischemic attacks, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389026\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">History of serious hypersensitivity reactions, including anaphylaxis to asparaginase (<i>Erwinia</i>) or any component of the formulation; history of serious pancreatitis, serious thrombosis, or serious hemorrhagic events with prior asparaginase treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Women who are or may become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389027\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Glucose intolerance: In clinical trials, 5% of patients experienced glucose intolerance; may be irreversible. Monitor glucose levels (baseline and periodic) during treatment. May require insulin administration. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Serious hypersensitivity reactions (grade 3 and 4), including anaphylaxis, have occurred in 5% of patients in clinical trials. Immediate treatment for hypersensitivity reactions should be available during treatment. Discontinue for serious hypersensitivity reactions (and administer appropriate treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Pancreatitis has been reported in 4% of patients in clinical trials. Promptly evaluate with symptoms suggestive of pancreatitis. For mild pancreatitis, withhold treatment until signs and symptoms subside and amylase levels return to normal; may resume after resolution. Discontinue for severe or hemorrhagic pancreatitis characterized by abdominal pain &gt;72 hours and amylase &ge;2 x ULN. Further use is contraindicated if severe pancreatitis is diagnosed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombosis and hemorrhage: Serious thrombotic events, including sagittal sinus thrombosis and pulmonary embolism, have been reported with asparaginase formulations. Discontinue for thrombotic event, may resume treatment after resolution. Decreases in fibrinogen, protein C activity, protein S activity, and antithrombin III have been noted following a 2-week treatment course administered intramuscularly. Discontinue for hemorrhagic event; may resume treatment after resolution (contraindicated with history of serious thrombosis or hemorrhagic event with prior asparaginase treatment).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Medication error prevention: Do not interchange <i>Erwinia</i> asparaginase for <i>E. coli</i> asparaginase or pegaspargase; ensure the proper formulation, route of administration, and dose prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13460902\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13460900\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=17098&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): Asparaginase (Erwinia) may increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389022\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389023\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389025\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if asparaginase <i>Erwinia chrysanthemi</i> is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389055\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, amylase, lipase, triglycerides, liver enzymes, blood glucose (baseline and periodically during treatment), coagulation parameters; for IV administration, consider monitoring nadir serum asparaginase activity (NSAA) levels. Monitor for symptoms of hypersensitivity, symptoms of pancreatitis, thrombosis, or hemorrhage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389037\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Asparaginase catalyzes the deamidation of asparagine to aspartic acid and ammonia, reducing circulating levels of asparagine. Leukemia cells lack asparagine synthetase and are unable to synthesize asparagine. Asparaginase reduces the exogenous asparagine source for the leukemic cells, resulting in cytotoxicity specific to leukemic cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13389039\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Half-life elimination: IM: ~16 hours (Asselin 1993; Avramis 2005); IV: ~7.5 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322923\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Erwinaze Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 unit (1): $4,696.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22059498\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Erwinase (AR, AT, DK, FR, GR, IE, JP, KR, LB, NL, NZ, PL, PT, SE, SG, TH, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Asselin BL, Whitin JC, Cappola DJ, et al, &ldquo;Comparative Pharmacokinetic Studies of Three Asparaginase Preparations,&rdquo; <i>J Clin Oncol</i>, 1993, 11(9):1780-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/8355045/pubmed\" target=\"_blank\" id=\"8355045\">8355045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avramis VI and Panosyan EH, &ldquo;Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations: The Past, the Present and Recommendations for the Future,&rdquo; <i>Clin Pharmacokinet</i>, 2005, 44(4):367-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/15828851/pubmed\" target=\"_blank\" id=\"15828851\">15828851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheung KC, van den Bemt PM, Torringa ML, et al, &ldquo;Erroneous Exchange of Asparaginase Forms in the Treatment of Acute Lymphoblastic Leukemia,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2011, 33(3):e109-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/21368672/pubmed\" target=\"_blank\" id=\"21368672\">21368672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duval M, Suciu S, Ferster A, et al, &ldquo;Comparison of <i>Escherichia Coli </i>-Asparaginase With <i>Erwinia</i>-Asparaginase in the Treatment of Childhood Lymphoid Malignancies: Results of a Randomized European Organisation for Research and Treatment of Cancer &minus; Children's Leukemia Group Phase 3 Trial,&rdquo; <i>Blood</i>, 2002, 99(8):2734-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erwinaze (asparaginase) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erwinase (asparaginase) [Canadian product monograph]. Lyon, France: Jazz Pharmaceuticals France SAS; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grace RF, Dahlberg SE, Neuberg D, et al, &ldquo;The Frequency and Management of Asparaginase-Related Thrombosis in Paediatric and Adult Patients With Acute Lymphoblastic Leukaemia Treated on Dana-Farber Cancer Institute Consortium Protocols,&rdquo; <i>Br J Haematol</i>, 2011, 152(4):452-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/21210774/pubmed\" target=\"_blank\" id=\"21210774\">21210774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salzer WL, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children&rsquo;s Oncology Group. <i>Blood</i>. 2013;122(4):507-514.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/23741010/pubmed\" target=\"_blank\" id=\"23741010\">23741010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrey D, Speitel K, Lanvers-Kaminsky C, et al, &ldquo;Five-Year Single-Center Study of Asparaginase Therapy Within the ALL-BFM 2000 Trial,&rdquo; <i>Pediatr Blood Cancer</i>, 2011, 57(3):378-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/21337682/pubmed\" target=\"_blank\" id=\"21337682\">21337682</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. <i>Leuk Lymphoma</i>. 2011;52(12):2237-2253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/21827361/pubmed\" target=\"_blank\" id=\"21827361\">21827361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vrooman LM, Supko JG, Neuberg DS, et al, &ldquo;<i>Erwinia</i> Asparaginase After Allergy to <i>E. coli</i> Asparaginase in Children With Acute Lymphoblastic Leukemia,&rdquo; Pediatr Blood Cancer, 2010, 54(2):199-205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/19672973/pubmed\" target=\"_blank\" id=\"19672973\">19672973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2008;26(12):1932-1939.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/18421047/pubmed\" target=\"_blank\" id=\"18421047\">18421047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zalewska-Szewczyk B, Gach A, Wyka K, et al, &ldquo;The Cross-Reactivity of Anti-Asparaginase Antibodies Against Different L-Asparaginase Preparations,&rdquo; <i>Clin Exp Med</i>, 2009, 9(2):113-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/erwinia-asparaginase-drug-information/abstract-text/19184328/pubmed\" target=\"_blank\" id=\"19184328\">19184328</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 17098 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F48847933\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13388919\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13382001\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13381923\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13389045\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13389044\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13389049\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13389048\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F13389047\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13388920\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F13389021\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F13389020\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13389050\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13381925\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13381921\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13389029\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13389026\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13389027\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13460902\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13460900\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13389022\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13389023\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13389025\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13389055\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13389037\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13389039\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322923\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22059498\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/17098|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=erwinia-asparaginase-patient-drug-information\" class=\"drug drug_patient\">Erwinia asparaginase: Patient drug information</a></li><li><a href=\"topic.htm?path=erwinia-asparaginase-pediatric-drug-information\" class=\"drug drug_pediatric\">Erwinia asparaginase: Pediatric drug information</a></li></ul></div></div>","javascript":null}